Navigation Links
BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD

A new drug, peramivir, claimed to be a highly potent formulation for combating the virulent forms of the H5N1 bird flu virus has been credited with a fast-track review by the Food and Drug Administration. //

This novel drug, produced by the pharmaceutical company BioCryst can be injected intravenously. Promising results have been obtained from drug trials conducted against different bird flu strains. If successful and approved we could soon have a new form of anti-viral therapy to effectively manage the bird flu threat.

"The FDA's decision supports our belief in the potential of peramivir as an effective therapy for the treatment of influenza, including highly virulent, life-threatening strains like those associated with avian influenza," said BioCryst Chairman and CEO Charles Bugg.

The FDA had approved the launch of human trials to test the efficacy and safety of the intravenous formulation of peramivir, last December. Following approval, it has been planned to initiate phase I clinical trials of the drug within March 2006. The drug would be tested on patients suffering from acute influenza infection.

In addition, developing an intramuscular form of the drug is also under consideration. This is belived to be tested on victims of seasonal bird flu. Both the clinical trials are jointly conducted by the National Institutes of Allergy and Infectious Diseases at the National Institute of Health.

Only those drugs, used for the treatment of severe diseases for which there is an unfulfiled medical need would be granted fast-track status by the FDA. A six month review of the sponsor’s drug by the FDA would also be included in the fast-track package.


Page: 1

Related medicine news :

1. Rural Population Enjoys Better Mental Health
2. Once-Diabetic Heart/Kidney/Pancreas Transplant Recipient Enjoys Life (And Eating Again)
3. Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses
4. US Reviews Risks Of Tamiflu After 12 Children Die
5. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
6. FDA Accords Priority Review For Pediatric Crohns Disease Drug
7. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
8. Review of Pramod Mahajans Injuries
9. Vaticans Council Reviews Condom Usage
10. Review of Reversal of Spread of Diseases in Africa
11. Closure of NHS Borders Hospitals to be Reviewed
Post Your Comments:

(Date:11/29/2015)... ... November 29, 2015 , ... NewsWatch featured X-wing as ... available to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted ... reality in the future. , It’s the future because flying cars are about to ...
(Date:11/29/2015)... ... , ... Effective immediately, every single IguanaMed scrub style will be available at ... offering a “Buy One Scrub Set, Get the 2nd Scrub Set 50% Off” for ... a discounted price. , IguanaMed’s mission is to outfit every healer around ...
(Date:11/28/2015)... ... ... at 6:00 a.m. EST until 11:59 p.m. EST, customers will be racing ... off orders $80 or more to free gifts with purchases, there will be a new ... e-commerce website for skin care and cosmetic needs, customers will save on already discounted prices. ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... that they are handling security in light of the recent terrorist attacks in Paris, ... attempt to stop an attack from reaching U.S. soil. Especially around special events that ...
(Date:11/27/2015)... ... 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion that ... of their purchase of lice treatment product. In addition, customers will receive a complimentary ... spokesperson. “Finding lice is a sure way to ruin the holidays, so we encourage ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology: